Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kazia Therapeutics ( (KZIA) ) just unveiled an update.
On February 3, 2025, Kazia Therapeutics updated its corporate presentation to highlight its ongoing efforts in oncology drug development, particularly with its key assets, paxalisib and EVT801. The company is actively conducting clinical trials across multiple cancer types, including glioblastoma and advanced solid tumors, and has received various FDA designations for its innovative approaches. This update underscores Kazia’s strategic position in the oncology field and its potential for significant market impact, especially with the anticipated commercial opportunities for its glioblastoma treatment, which is projected to have a market size of $1.5 billion annually.
More about Kazia Therapeutics
Kazia Therapeutics is a late-clinical-stage oncology drug development company focused on developing differentiated clinical-stage assets. The company’s primary products include paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, and EVT801, a selective VEGFR3 inhibitor, both of which are in various stages of clinical trials for different types of cancers. Kazia operates with a licensing-driven business model and is solely listed on NASDAQ after delisting from the ASX in November 2023.
YTD Price Performance: -9.46%
Average Trading Volume: 1,868,770
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $6.88M
For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.
